A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

2019 ◽  
Author(s):  
Keyword(s):  
Clinical Practice ◽  
Disease Control ◽  
Russian Federation ◽  
Treatment Patterns ◽  
Routine Clinical Practice ◽  
The Russian Federation

scholarly journals A Multicenter, Prospective, Noninterventional Study in a Norwegian Cohort of Patients with Moderate-to-Severe Allergic Rhinitis Treated with MP-AzeFlu

2017 ◽  
Vol 8 (3) ◽  
pp. ar.2017.8.0216 ◽  
Author(s):  
Ralph Dollner ◽  
Petter Lorentz Larsen ◽  
Sinan Dheyauldeen ◽  
Sverre Steinsvåg
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Practice ◽  
Disease Control ◽  
Symptom Severity ◽  
Symptom Control ◽  
Real Life ◽  
Routine Clinical Practice ◽  
Vas Score ◽  
Receive Treatment ◽  
Noninterventional Study

Background Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control Objectives To evaluate the effectiveness of MP-AzeFlu (Dymista®) by using this VAS in routine clinical practice in Norway. MP-AzeFlu comprises a novel formulation that contains azelastine hydrochloride, fluticasone propionate and excipients delivered in a single spray. Methods This multicenter, prospective, noninterventional study enrolled patients (n = 160) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its summary of product characteristics. Patients assessed symptom severity by using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP-AzeFlu use on days 0, 1, 3, 7, and after ~14 days. On day 3, the patients assessed their level of disease control as well controlled, partly controlled, or uncontrolled. The proportion of Norwegian patients who achieved defined VAS score cutoffs for “well-controlled” and “partly controlled” AR were also calculated. Results MP-AzeFlu reduced the mean ± standard deviation VAS score from 68.1 ± 16.4 mm at baseline to 37.4 ± 25.9 mm on the last day, a reduction of 30.8 ± 27.2 mm. The results were consistent, irrespective of disease severity, phenotype (i.e., seasonal AR [SAR], perennial AR [PAR], SAR plus PAR, unknown) or age (i.e., 12–17, 18–65, and >65 years). Of the patients (with recorded data), 88.1% considered their symptoms to be partly or well controlled at day 3; and 19.5, 32.0, 50.0, and 61.0% of the patients achieved a ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7, and the last day, respectively. Conclusions MP-AzeFlu provided rapid sustained symptom control in a routine clinical practice in Norway, which provided support for its effectiveness for the treatment of AR in real life.

scholarly journals Atrial fibrillation treatment in Russia: work on bugs

2021 ◽  
Vol 28 (3) ◽  
pp. 1-4
Author(s):  
S. G. Kanorskii
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Russian Federation ◽  
Medical Errors ◽  
Clinical Guidelines ◽  
The Future ◽  
The Russian Federation ◽  
Real Clinical Practice

The article discusses the results of a survey of doctors in the Russian Federation with the aim of studying approaches to the treatment of atrial fibrillation in real clinical practice and comparing the results obtained with the current clinical guidelines. Some new data are presented that could change the recommendations in the future; possible causes of medical errors and ways to correct them are discussed.

scholarly journals ALCOHOL AND THE RISK OF NON-COMMUNICABLE DISEASE: CONTROL STRATEGIES IN THE RUSSIAN FEDERATION

2013 ◽  
Vol 12 (4) ◽  
pp. 4-9 ◽  
Author(s):  
G. Ya. Maslennikova ◽  
R. G. Oganov
Keyword(s):  
Disease Control ◽  
Russian Federation ◽  
Communicable Disease ◽  
Control Strategies ◽  
Communicable Disease Control ◽  
The Russian Federation ◽  
Non Communicable Disease

Alcohol and the risk of non-communicable disease: control strategies in the Russian Federation.

scholarly journals Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

2020 ◽  
pp. 69-79
Author(s):  
A. A. Gruzdeva ◽  
A. A. Khokhlov ◽  
M. V. Ilyin
Keyword(s):  
Clinical Practice ◽  
Medical Care ◽  
Russian Federation ◽  
Oral Anticoagulants ◽  
Warfarin Dose ◽  
Thromboembolic Complications ◽  
Russian Market ◽  
Drug Reimbursement ◽  
Anticoagulation Clinics ◽  
The Russian Federation

In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC). The appearance on the Russian market of new oral anticoagulants (NOAC) has become a help for doctors, however, their cost imposes restrictions on the use. A humanitarian aid drugs to medical organizations of the RF, an active information program from manufacturers over the past 1.5 years have significantly increased the use of NOAC. In different regions, a different situation arises regarding the procurement and frequency of use of one or another anticoagulant. Analyzing the procurement of additional drug supplies for different regions of the Russian Federation, we see that dabigatran is preferred in a number of regions of the Central Federal District, and rivaroxaban in the Northern regions. The cost of warfarin is low. Data on the important role of the genotype in determining the individual dose and the development of bleeding, which is associated with the metabolism of warfarin, have been obtained. The pharmacogenetic approach allows you to quickly and efficiently choose its dose. The use of generics is highly relevant on the Russian market. Also, a number of regions are of great interest as a basis for conducting clinical trials of drugs. Aim. To analyze the current use of anticoagulant drugs taking into account personalized treatment approaches (the implementation of pharmacogenetic examinations and the work of anticoagulation clinics). Methods. Analysis of real clinical practice in the Russian Federation, patient registries, evaluation of adverse events in anticoagulation therapy and pharmacogenetic studies. Analysis of anticoagulant purchase under the Drug Reimbursement Program in several regions of the RF. Evaluation of the effect of anticoagulation clinics throughout the RF. Results. We analyzed the use of anticoagulants. To reduce the risk of thromboembolic complications and select the appropriate antithrombotic therapy, the entire range of antithrombotic agents is required, including NOACs and vitamin K antagonists (warfarin). Th e appearance of warfarin and NOACs on the Russian market has significantly improved the quality of medical care and treatment outcomes in these patients. Active awareness raising, the addition of anticoagulants to the national clinical guidelines and to clinical practice, and state support as part of the Drug Reimbursement Program have significantly increased the frequency of anticoagulant use. Nevertheless, the frequency of anticoagulant use varies slightly between regions. Warfarin is the most widely used anticoagulant and has high affordability (from 44 to 72.5 % out of all anticoagulants). The frequency of bleeding does not differ significantly between different anticoagulants, with an average of 2.8 %. A first INR value of ≥2.0 aft er 3-5 days is significantly associated with over coagulation during warfarin dose titration. The rapid achievement of an anticoagulation effect is often associated with a specific genotype (CYP2C9*2/*2, *3/*3 and 2/*3 variants and A/A of the VKORC1 gene, or CYP2C9 and VKORC1 polymorphism). Pharmacogenomics-guided warfarin dosing in clinical practice allows the warfarin dose to be selected in a faster and more effective way and for the risk of adverse reactions to be reduced. The creation of a network of anticoagulation clinics has proven to be highly effective. The most well-structured system of anticoagulation clinics is present in the Kursk Region. Rivaroxaban was the biggest selling anticoagulant out of the NOACs on the Russian sales market in 2018, but given the growth in apixaban sales, it is likely that this NOAC will move into first place in the near future.Conclusion. A personalized approach to anticoagulant use is crucial for the prevention of thromboembolic complications.

scholarly journals 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

2021 ◽  
Vol 26 (5) ◽  
pp. 4541
Author(s):  
S. A. Gabrusenko ◽  
A. Ya. Gudkova ◽  
N. A. Koziolova ◽  
S. A. Alexandrova ◽  
M. I. Berseneva ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Hypertrophic Cardiomyopathy ◽  
Russian Federation ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Task Force ◽  
Russian Society ◽  
Ministry Of Health ◽  
The Russian Federation ◽  
Russian Association

Russian Society of Cardiology (RSC)With the participation: Russian Association of Cardiovascular SurgeonsEndorsed by: Research and Practical Council of the Ministry of Health of the Russian Federation Task Force: Gabrusenko S.A. (Chairman), Gudkova A.Ya.* (Chairman), Koziolova N.A. (Chairman), Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Yu., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V.

scholarly journals Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

2020 ◽  
Vol 10 (1) ◽  
pp. 65-72
Author(s):  
E. V. Borodavina ◽  
P. A. Isaev ◽  
A. Yu. Shurinov ◽  
P. O. Rumyantsev ◽  
V. V. Krylov ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Practice ◽  
Russian Federation ◽  
Differentiated Thyroid Cancer ◽  
Progression Free Survival ◽  
Good Tolerability ◽  
Study Objective ◽  
Free Survival ◽  
Median Progression Free Survival ◽  
The Russian Federation

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation. Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study. Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation.

Sign in / Sign up

Export Citation Format

Share Document